The deals tout significant discounts for people who pay out of pocket for certain medications. But most people with insurance ...

A new study finds that people who quit weight-loss medications including GLP-1s regain weight four times faster than people ...

Millions of Americans are using GLP-1s. But so far, there has been comparatively less research on what happens when users ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Experts emphasized that obesity is a chronic, relapsing condition and lifelong therapy—in some form—will be necessary.

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing ...

People taking weight-loss drugs are likely to regain the weight they have lost within two years of stopping the medications, ...

Year after year, Mary Bucklew strategized with a nurse practitioner about losing weight. “We tried exercise,” like walking 35 ...

Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA ...